Kuehn Law Launches Investigation Into Regenxbio Over Gene Therapy Claims
Shareholders of Regenxbio, Inc. are facing a potential legal reckoning as Kuehn Law, PLLC, investigates whether company leadership misled investors regarding the safety and efficacy of its RGX-111 gene therapy. The inquiry centers on allegations that executives issued overly optimistic trial data to bolster the company’s market standing.
The investigation focuses on assertions made by Regenxbio regarding the Phase I/II study for RGX-111, a treatment designed for Hurler Syndrome. According to a federal securities lawsuit, the company allegedly provided false or misleading information to the market, specifically concerning the drug's projected success based on biomarker data. Investors who held RGNX shares prior to February 9, 2022, are being urged to come forward as the firm evaluates potential breaches of fiduciary duty.
Kuehn Law, based in Southampton, New York, is soliciting contact from affected parties to determine the scope of the alleged misconduct. The firm has stated it covers all case costs for clients, emphasizing that shareholders should act quickly due to potential legal deadlines. Interested parties can reach out to Sophia Anne Silayan at the firm to discuss their rights and the implications of the ongoing derivative litigation.
Comments (0)
No comments yet. Be the first!